Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, explains the Agreement of a Single IRB Review | Single IRG Approval…
Browsing: Pancreatic
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, shares how the Study Brought Together Six Academic Centers | BMS, Apexigen,…
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, explains how No One Else is Focusing on Pancreatic Cancer | Answer…
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, explains that the study Focuses on Frontline Metastatic Pancreatic Cancer | Patients…
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, explains that the study Follows Patients for a Period of Time in…
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, talks about Lead Investigator of Study, Dr. Vonderheide | Develop New Agents…
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, explains the combination of Gemcitabine + Abraxane – Standard for Pancreatic Cancer…
Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, talks about the Trial Combining Immunotherapy & Chemotherapy | Survival will be…
John Leighton, MD, explains shares the results of the PREOPANC-1 study and, resectable pancreatic cancer patients should recieve preoperative chemotherapy…
Al Benson III, MD, FACP, Professor of Medicine, Northwestern University, shares the outcomes of the ECOG-ACRIN study in advanced pancreatic…
In this interview, Jeff Evans, PhD, from the University of Glasgow, Glasgow, UK, provides an update on the current landscape…
Jon Eckard, PhD, TYME Inc., explains Not Much Getting Approval for Pancreatic Cancer | Cost of cancer care is very…
Jon Eckard, PhD, TYME Inc., explains Taking Advantage of the Metabolism of a Cancer Delivering drug specifically to the cancer…
Jon Eckard, PhD, TYME Inc., explains Ongoing Phase II Pancreatic Cancer Trial Metabolic therapy is tumor-treating, patient-sparing at Annual Meeting…